American Association for Cancer Research
crc-22-0278-s04.pdf (845.59 kB)

Figure S2 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling

Download (845.59 kB)
journal contribution
posted on 2023-04-04, 02:21 authored by Israel Matos, Maunish Barvalia, Manreet K. Chehal, A. Gordon Robertson, Iva Kulic, Jessica A.F.D. Silva, Abhinandan Ranganathan, Amy Short, Yu-Hsuan Huang, Erin Long, John J. Priatel, Salim Dhanji, Brad H. Nelson, Danielle L. Krebs, Kenneth W. Harder

Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised and G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.


Gouvernement du Canada | Canadian Institutes of Health Research (IRSC)

Michael Smith Health Research BC (MSFHR)

Canadian Breast Cancer Foundation



Tumor-derived GCSF leads to systemic immune population changes. GCSF blockade restores immune populations, improves immunotherapy, and reduces tumor size, paralleling human colorectal cancer data. GCSF inhibition may synergize with current immunotherapies to treat GCSF-secreting tumors.